Proteomics

Dataset Information

0

Kinome Profiling of Gastrointestinal Stromal Tumors Using Multiplexed Inhibitor Beads and Mass Spectrometry Identifies Wee1 as a Candidate Therapeutic Target


ABSTRACT: Purpose: Management of gastrointestinal stromal tumor (GIST) has been revolutionized by the identification of activating mutations in KIT and PDGFRA and the clinical application of receptor tyrosine kinase (RTK) inhibitors in the advanced disease setting. Stratification of GIST into molecularly defined subsets provides insight into clinical behavior and response to approved targeted therapies. Although these RTK inhibitors are effective in the majority of GIST, resistance to these agents remains a significant clinical obstacle. Development of effective treatment strategies for refractory GIST requires identification of novel targets to provide additional therapeutic options. Global kinome profiling has the potential to identify critical signaling networks and reveal protein kinases that are essential in GIST. Experimental Design: Using Multiplexed Inhibitor Beads and Mass Spectrometry paired with a super-SILAC kinome standard, we explored the majority of the kinome in GIST specimens from three GIST subtypes (KIT-mutant, PDGFRA-mutant and succinate dehydrogenase-deficient GIST) to identify novel kinase targets. In vitro and in vivo studies were performed to evaluate the utility of targeting the identified kinases in GIST. Results: Kinome profiling revealed distinct signatures in three GIST subtypes. PDGFRA-mutant GIST had elevated tumor associated macrophage (TAM) kinases and immunohistochemical analysis confirmed increased TAMs present in these tumors. Kinome profiling with loss-of-function assays revealed a significant role for G2-M tyrosine kinase, Wee1, in GIST survival. In vitro and in vivo studies revealed significant efficacy of MK-1775 (Wee1 inhibitor) in combination with avapritinib in both KIT and PDGFRA-mutant GIST cell lines, as well as notable efficacy of MK-1775 as a single agent in the PDGFRA-mutant line. Conclusions: These studies provide strong preclinical justification for the use of MK-1775 in GIST.

INSTRUMENT(S): Q Exactive

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Gastrointestinal Stromal Tumor Cell

SUBMITTER: Lori RInk  

LAB HEAD: Lori Rink

PROVIDER: PXD020720 | Pride | 2021-09-09

REPOSITORIES: Pride

Dataset's files

Source:
Action DRS
160318_JD_QE2_D_Rink_sample_01.raw Raw
160318_JD_QE2_D_Rink_sample_02.raw Raw
160318_JD_QE2_D_Rink_sample_03.raw Raw
160318_JD_QE2_D_Rink_sample_04.raw Raw
160318_JD_QE2_D_Rink_sample_05.raw Raw
Items per page:
1 - 5 of 52
altmetric image

Publications


Management of gastrointestinal stromal tumors (GISTs) has been revolutionized by the identification of activating mutations in KIT and PDGFRA and clinical application of RTK inhibitors in advanced disease. Stratification of GISTs into molecularly defined subsets provides insight into clinical behavior and response to approved targeted therapies. Although these RTK inhibitors are effective in most GISTs, resistance remains a significant clinical problem. Development of effective treatment strateg  ...[more]

Similar Datasets

2020-09-30 | PXD020357 | Pride
2022-02-17 | PXD025819 | Pride
2020-02-19 | PXD015783 | Pride
2020-02-19 | PXD015781 | Pride
2020-02-19 | PXD015849 | Pride
| PRJNA824718 | ENA
2020-02-19 | PXD015782 | Pride
2009-09-05 | E-GEOD-17743 | biostudies-arrayexpress
2023-03-10 | PXD030571 | Pride
2024-04-23 | PXD033921 | Pride